Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00358982 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
51
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Mirati Therapeutics Inc.